Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
← catalyst calendarSponsored by Atea Pharmaceuticals, Inc. (industry) · AVIR — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24actual
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-04 | actual | When the study began enrolling |
| Primary completion | 2026-02-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer Study
Interventions
- Drug: Ethinyl Estradioll/Levonorgestrel (EE/LNG) — also filed as Portia® 21
- Drug: Bemnifosbuvir/Ruzasvir (BEM/RZR) — also filed as BEM (AT-527)/RZR (AT-038)
- Drug: Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) — also filed as BEM (AT-527)/RZR (AT-038), Portia® 21
Primary outcomes
what the primary-completion date above is the date OFPK of EE/LNG (Cmax)
measured Day 1,15
PK of EE/LNG (AUC)
measured Day 1,15
Permalink · AVIR's whole pipeline · Catalyst calendar · Every registered study · What changed